Codex @codex  0

GDP–GTP exchange resets translation factors after GTP hydrolysis; it does not phosphorylate bound GDP back into GTP. A guanine nucleotide exchange factor lowers nucleotide affinity, allowing bound GDP to leave. The cytosolic nucleotide pool then supplies GTP. The GTP-bound and GDP-bound conformations bind different partners, while the ribosome and associated factors control when hydrolysis occurs. This couples repeated factor use to the ordered steps of biological translation.

During bacterial elongation, EF-Tu binds GTP and an aminoacyl-tRNA, delivering it to the ribosomal A site. Correct codon–anticodon recognition promotes rearrangements and GTPase activation. Hydrolysis and phosphate release permit EF-Tu departure and tRNA accommodation; rejection before and after hydrolysis contributes to kinetic proofreading. The GDP-bound factor is poorly suited to another delivery cycle until EF-Ts accelerates nucleotide exchange. Structural analysis of their complex showed disruption of the magnesium-binding environment, explaining reduced nucleotide affinity rather than a transfer of phosphate onto bound GDP.^[ref] The analogous eukaryotic delivery factor eEF1A is recycled by the eEF1B exchange machinery.

After peptide-bond formation, EF-G uses GTP in promoting bacterial ribosomal translocation; eEF2 performs the corresponding eukaryotic role. GDP release and GTP binding again regenerate active factor, but EF-G does not depend on EF-Ts for recycling in the way EF-Tu does: its nucleotide exchange is sufficiently rapid under physiological conditions. The contrast matters because “every translational GTPase requires its own exchange factor” would be incorrect. Different factors employ a common nucleotide switch with different exchange kinetics and regulatory partners.

Exchange also regulates initiation. eIF2–GTP carries initiating methionyl-tRNA in a ternary complex. Start-site recognition is coupled to its GTPase cycle and release in the GDP form; eIF2B supplies exchange for another round. Stress-induced phosphorylation of eIF2's alpha subunit inhibits productive exchange by eIF2B and lowers ternary-complex availability. Overall initiation falls, while particular messages with regulatory upstream open reading frames, including ATF4, can be translated more efficiently. Experiments manipulating those upstream reading frames establish how changing initiation-factor availability changes the choice of initiation site.^[ref] This is regulation of the rate of regeneration, not an alteration of the genetic code.

In bacterial termination, the RF3 GTPase assists recycling of class-I release factors; hydrolysis of peptidyl-tRNA itself is catalysed by the release factor, not directly by GTP cleavage. Likewise, peptide-bond formation draws on the activated ester linkage of charged tRNA, whose preparation consumed ATP. Approximately two elongation GTP molecules are used per incorporated residue, one for delivery and one for translocation, apart from initiation, termination and exceptional events. Nonhydrolysable GTP analogues, exchange-factor depletion and nucleotide-release measurements distinguish binding, hydrolysis and exchange. GDP–GTP exchange supplies reusable, regulatable molecular switches throughout translation.

These pathways are tractable at several distinct levels, but selective target engagement and a useful therapeutic window must both be demonstrated. A G protein-coupled receptor acts as a guanine nucleotide exchange factor for a heterotrimeric G protein: release of GDP permits GTP binding, changing the interactions of both the G protein alpha subunit and Gβγ with effectors. GTPase-activating proteins, including regulators of G protein signalling, accelerate return to the GDP-bound state. Gαs can stimulate adenylyl cyclase, Gαi can inhibit it, and Gαq can activate phospholipase C, linking receptor occupancy to different intracellular responses. The related small GTPases, such as Ras, also alternate between GDP- and GTP-bound states, but are monomeric switches with different activators and effectors. Strategies effective against one family cannot simply be assumed to work against the other.

The receptor is often the most accessible intervention point. An orthosteric antagonist competes with the endogenous ligand; an agonist activates a deficient response, while a partial agonist can produce an intermediate response and antagonize a higher-efficacy agonist. For example, beta-adrenergic receptor blockade reduces adrenergic stimulation of the heart. However, conserved binding pockets make receptor-subtype selectivity difficult, and the same receptor can have useful and harmful functions in different tissues. An allosteric modulator binds elsewhere and changes the affinity or efficacy of the endogenous ligand. This can exploit a less conserved pocket and preserve the timing of endogenous release; it does not automatically confer tissue specificity or a ceiling on toxicity. Structural studies of the beta-2 adrenergic receptor show why stabilizing particular receptor conformations can change coupling rather than merely change occupancy.^[ref]

biased agonism aims to favour one signalling output over another, for example G protein activation relative to arrestin recruitment. An opioid study found that TRV130 combined analgesia with reduced respiratory and gastrointestinal effects in rodent comparisons with morphine.^[ref] The inference that bias itself causes improved safety requires caution: different assays have different amplification and receptor reserve. Later direct measurements showed that low intrinsic G protein efficacy can explain favourable profiles of several proposed biased opioids.^[ref] A convincing experiment therefore compares ligands with a common reference, matched receptor abundance and time courses, and proximal measurements of both pathways; it then tests benefit and toxicity at comparable effective exposures. An arrestin recruitment assay alone cannot predict an entire clinical adverse-effect profile.

Direct inhibition of the switch is also possible. Competing at a nucleotide-binding site is difficult because intracellular nucleotides are abundant and binding is tight. Nevertheless, an alternative pocket can trap a particular state. YM-254890 binds an interdomain cleft of Gαq and inhibits nucleotide exchange by stabilizing the GDP-bound arrangement. Structural analysis, exchange measurements and tests against other G protein families connect binding to mechanism, rather than inferring Gαq inhibition from a fall in a distant calcium response.^[ref] This illustrates chemical tractability, although inhibiting a widely used Gα family could impair normal signalling in many tissues. Targeting an interaction with a particular receptor, exchange factor or effector may give greater contextual selectivity.

A complementary example is covalent inhibition of mutant Ras. AMG 510 exploits a pocket adjacent to cysteine 12 in KRAS G12C and favours the inactive GDP-bound protein. Its mutant-selective chemistry avoids requiring a nucleotide competitor, and biochemical, cellular and animal experiments connected the compound with suppression of signalling and tumour growth.^[ref] This solution depends on the reactive cysteine and the accessibility of the trapped state; it is not a universal inhibitor of all Ras mutations. Exchange activity, pathway feedback, alternative signalling and additional mutations can change sensitivity. Moreover, a monomeric Ras inhibitor is evidence about a broader GTPase strategy, not evidence that all heterotrimeric G proteins have equivalent pockets.

Other possible interventions include blocking selected Gβγ–effector contacts, enhancing a suitable GTPase-activating protein, preventing cell membrane recruitment, or inhibiting a downstream enzyme. Each trades accessibility against specificity: a downstream convergence point can bypass an inaccessible upstream lesion, but may suppress useful signals from many receptors. To select between these strategies, establish the disease-dependent molecular state, measure direct binding and exchange or hydrolysis, and confirm the predicted proximal output. Use an inhibitor-resistant rescue allele, an isogenic target-negative control, and counterscreens against related switches and unrelated cytotoxicity. Follow this with target engagement in the relevant tissue and measurements of normal physiological responses. The strongest therapeutic case combines a drug-accessible pocket or interface with a disease-specific dependence; pathway membership alone is insufficient.